- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02381561
Ropidoxuridin bei der Behandlung von Patienten mit fortgeschrittenem Magen-Darm-Krebs, die sich einer Strahlentherapie unterziehen
Phase-I- und pharmakologische Studie zu oraler 5-Iod-2-Pyrimidinon-2'-Desoxyribose (IPdR) als Prodrug für IUdR-vermittelte Radiosensibilisierung von Tumoren bei Magen-Darm-Krebs
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment undergoing radiation therapy. Ropidoxuridine may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy.
Studienübersicht
Status
Bedingungen
- Bauchspeicheldrüsenkrebs im Stadium III AJCC v6 und v7
- Bauchspeicheldrüsenkrebs im Stadium IV AJCC v6 und v7
- Speiseröhrenkrebs im Stadium IV AJCC v7
- Magenkrebs im Stadium IV AJCC v7
- Leberkrebs im Stadium III
- Leberkrebs im Stadium IV
- Darmkrebs im Stadium III AJCC v7
- Rektumkarzinom im Stadium III AJCC v7
- Darmkrebs im Stadium IIIA AJCC v7
- Rektumkarzinom im Stadium IIIA AJCC v7
- Darmkrebs im Stadium IIIB AJCC v7
- Stadium IIIB Rektumkarzinom AJCC v7
- Darmkrebs im Stadium IIIC AJCC v7
- Rektumkarzinom im Stadium IIIC AJCC v7
- Darmkrebs im Stadium IV AJCC v7
- Stadium IV Rektumkarzinom AJCC v7
- Darmkrebs im Stadium IVA AJCC v7
- Rektumkarzinom im Stadium IVA AJCC v7
- Darmkrebs im Stadium IVB AJCC v7
- Rektumkarzinom im Stadium IVB AJCC v7
- Bauchspeicheldrüsenkrebs im Stadium II AJCC v6 und v7
- Bauchspeicheldrüsenkrebs im Stadium IIA AJCC v6 und v7
- Bauchspeicheldrüsenkrebs im Stadium IIB AJCC v6 und v7
- Magenkrebs im Stadium III AJCC v7
- Magenkrebs im Stadium IIIA AJCC v7
- Magenkrebs im Stadium IIIB AJCC v7
- Magenkrebs im Stadium IIIC AJCC v7
- Fortgeschrittenes Gallengangskarzinom
- Speiseröhrenkrebs im Stadium II AJCC v7
- Speiseröhrenkrebs im Stadium IIA AJCC v7
- Speiseröhrenkrebs im Stadium IIB AJCC v7
- Speiseröhrenkrebs im Stadium III AJCC v7
- Stadium III Dünndarmkrebs AJCC v7
- Speiseröhrenkrebs im Stadium IIIA AJCC v7
- Dünndarmkrebs im Stadium IIIA AJCC v7
- Speiseröhrenkrebs im Stadium IIIB AJCC v7
- Stadium IIIB Dünndarmkrebs AJCC v7
- Speiseröhrenkrebs im Stadium IIIC AJCC v7
- Stadium IV Dünndarmkrebs AJCC v7
- Leberkrebs im Stadium IVA
- Leberkrebs im Stadium IVB
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To conduct a phase I dose escalation trial, to determine the safety and the maximum tolerated dose (MTD), of oral (po) IPdR (ropidoxuridine) given daily for 28 consecutive days with concurrent intensity-modulated radiation therapy (IMRT) in patients with advanced gastrointestinal cancers treated with palliative radiation.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity. II. To establish the pharmacokinetics of daily po dosing of IPdR x 28 days. III. To assess, for patients treated at the MTD, for biochemical evidence of IPdR effect in normal tissue (circulating granulocytes) and tumor tissue (in patients with accessible tumor tissue) by measuring %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) cellular incorporation by flow cytometry and high-pressure liquid chromatography (HPLC) analyses.
IV. To assess the use of %IUdR-DNA cellular incorporation (measured by the investigational laboratory assays of flow cytometry and HPLC) as an exploratory biomarker of IPdR for the following effects: the %IUdR-DNA tumor cell incorporation from day 8 tumor biopsies in gastrointestinal (GI) cancer patients receiving MTD doses of IPdR as an exploratory biomarker of tumor radiosensitization using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
V. To assess the use of %IUdR-DNA cellular incorporation (measured by the investigational laboratory assays of flow cytometry and HPLC) as an exploratory biomarker of IPdR for the following effects: the %IUdR-DNA cellular incorporation in patients' circulating granulocytes taken weekly during the 28-day IPdR MTD dose, on day 29, and week 8 as an exploratory biomarker of IPdR systemic toxicities to bone marrow as measured by complete blood count (CBC)/differential values.
OUTLINE: This is a dose-escalation study of ropidoxuridine.
Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO once daily (QD) on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rhode Island Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed advanced, incurable cancers of the esophagus, liver, stomach, small bowel, pancreas, bile duct, colon or rectum and be eligible to receive chest, abdominal and/or pelvic radiation therapy (RT) for palliation; documentation of this is required in physician note; concomitant systemic therapy is not allowed during administration of palliative RT; palliative RT can be considered for advanced primary tumors or metastatic disease as above
- Patients must not have received systemic chemotherapy for at least 4 weeks, and must not have received prior radiation therapy to the tumor site being irradiated on this study
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 12 weeks
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of IPdR administration
- Ability to understand and the willingness to sign a written informed consent document
- Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy
- Women of child-bearing potential must have a negative pregnancy test
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients who are receiving any other investigational agents
- Patients with known brain metastases should be excluded from this clinical trial
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Treatment (ropidoxuridine, IMRT)
Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity. |
Correlative studies Correlative studies Undergo IMRT
Andere Namen:
Given PO
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Die maximal tolerierte Dosis (MTD) ist definiert als die Dosis, unterhalb der bei 2 oder mehr von 6 Patienten eine dosislimitierende Toxizität auftritt
Zeitfenster: Bis zu 28 Tage
|
Bis zu 28 Tage
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in tumor biopsies
Zeitfenster: Up to 2 weeks
|
Correlate %IUdR-DNA incorporation in human gastrointestinal (GI) tumor biopsies in the proposed phase I and pharmacokinetic (PK) clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic radiation therapy (RT) by linear regression. |
Up to 2 weeks
|
|
Pharmacokinetic (PK) incorporation in tumor biopsies
Zeitfenster: Days 1, 15 and 22 before drug administration, at 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression. |
Days 1, 15 and 22 before drug administration, at 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
|
%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in peripheral (circulating) granulocytes
Zeitfenster: Up to 4 weeks after completion of study treatment
|
Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression. |
Up to 4 weeks after completion of study treatment
|
|
Pharmacokinetic (PK) incorporation in peripheral (circulating) granulocytes
Zeitfenster: Days 1, 15 and 22 before drug administration, 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression. |
Days 1, 15 and 22 before drug administration, 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration
|
|
Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements
Zeitfenster: Day 8
|
Tumor response is the dependent variable and can be binomial (i.e. response versus [vs.] no response) or multinomial (i.e. complete response, partial response, stable disease or progressive disease) and the %IUdR-DNA incorporation is the independent variable. |
Day 8
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Timothy J Kinsella, Rhode Island Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Darmerkrankungen
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Magenerkrankungen
- Kolorektale Neubildungen
- Darmtumoren
- Rektale Erkrankungen
- Kopf-Hals-Neubildungen
- Leberkrankheiten
- Darmerkrankungen
- Erkrankungen der Speiseröhre
- Magenneoplasmen
- Rektale Neoplasien
- Darmneoplasmen
- Ösophagusneoplasmen
- Lebertumoren
- Therapeutika
- Strahlentherapie
- Strahlentherapie, konform
- Strahlentherapie, computergestützt
- Strahlentherapie, intensität moduliert
- Ropidoxuridin
Andere Studien-ID-Nummern
- NCI-2015-00258
- NCI-2015-00258 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- BRUOG 265
- 9882 (Andere Kennung: CTEP)
- 9882 (Andere Kennung: Rhode Island Hospital)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .